CBDV Begins Psilocybin Research
CBDV BEGINS RESEARCH ON PSILOCYBIN WITH SECTION 56 EXEMPTION FROM HEALTH CANADA CBDV will develop analytical methods for psilocybin and identify new medicinally relevant mushroom metabolites. VANCOUVER, BC, CANADA, January 14 2021. Complex Biotech Discovery Ventures Ltd. (“CBDV” or the “Company”), a licensed cannabis and psilocybin research laboratory specializing in extraction, chemical analytics, and process …
